For the Inventor, By the Inventor

Enter assignee name

Rottapharm Biotech S.r.l.

Calculating rank

USPTO Granted Patents = 17

% Expired Patents = 52.9

CIPO Patents = 5

EPO Patents = 25

Forward Citations = 19

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Lucio C Rovati (17 out of 59 patents)

Gianfranco Caselli (7 out of 28 patents)

Luigi Piero Stasi (7 out of 10 patents)

4. Roberto Artusi (4 out of 11 patents)

5. Filippo Magaraci (4 out of 4 patents)

6. Fabrizio Colace (3 out of 4 patents)

7. Manuela Borriello (3 out of 3 patents)

8. Sabrina Pucci (3 out of 4 patents)

9. Antonio Giordani (3 out of 30 patents)

10. Benedetta Buzzi (3 out of 3 patents)

11. Tiziana Piepoli (3 out of 5 patents)

12. Michela Visintin (2 out of 5 patents)

13. Stefano Mandelli (2 out of 9 patents)

14. Daniele Maggioni (2 out of 2 patents)

15. Albino Bonazzi (2 out of 2 patents)

17 patents: Sort by Forward Citations

1. 12544365 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2026-02-10),

2. 12509446 - FYN and VEGFR2 kinase inhibitors (2025-12-30),

3. 12433875 - (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification (2025-10-07),

4. 12404245 - Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof (2025-09-02),

5. 11718582 - (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist (2023-08-08),

6. 11590114 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2023-02-28),

7. 10125121 - FYN kinase inhibitors (2018-11-13),

8. 9631029 - Anti-ADAMTS-5 antibody, derivatives and uses thereof (2017-04-25),

9. 9498478 - Spiro aminic compounds with NK1 antagonist activity (2016-11-22),

10. 9365654 - Anti-TrkA antibodies, derivatives and uses thereof (2016-06-14),

11. 9181279 - [object Object] (2015-11-10),

12. 9174977 - 2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders (2015-11-03),

13. 9162979 - 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors (2015-10-20),

14. 9120824 - [object Object] (2015-09-01),

15. 9062033 - Chemical compounds (2015-06-23),

Company Overview

Rottapharm Biotech S.r.l., based in Monza, Italy, is a prominent player in the biopharmaceutical sector, focusing on the development and manufacturing of innovative therapeutic solutions. The company specializes in areas such as oncology, immunology, and rare diseases, leveraging advanced biotechnological processes to create high-quality products. With a commitment to research and development, Rottapharm aims to address unmet medical needs and improve patient outcomes through its cutting-edge therapies and collaborations in the global healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

17 Patents

#2 in Monza

#537 in Italy

#35,987 in the World

Rottapharm Biotech S.r.l.

Forward Citations = 19

24 inventors:

Lucio C Rovati (17 out of 59 patents)

Gianfranco Caselli (7 out of 28 patents)

Luigi Piero Stasi (7 out of 10 patents)

4. Roberto Artusi (4 out of 11 patents)

5. Filippo Magaraci (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rottapharm Biotech S.r.l.. Retrieved from https://idiyas.com/company/rottapharm-biotech-s-r-l

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…